Smad3 Signaling in the Regenerating Liver: Implications for Regulation of IL6 Expression

Michael Kremer[1,2,*], **Gakuhei Son**[2,*], **Kun Zhang**[3], **Sherri M. Moore**[3], **Amber Norris**[3], **Giulia Manzini**[1], **Michael D Wheeler**[3], and **Ian N Hines**[2,3]

[1]Department of General Surgery, University of Ulm, Ulm, Germany

[2]Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599

[3]Department of Nutrition Science, East Carolina University, Greenville, NC 27858

Abstract

Liver regeneration is vital for graft survival and adequate organ function. Smad activation regulates hepatocyte proliferation and macrophage function. Aim of the current study is to evaluate the impact of Smad3 signaling during liver regeneration in the mouse.

Male C57/Bl6 wild type (wt) mice or mice deficient in Smad3 (Smad3$^{-/-}$) were subjected to a 70% partial hepatectomy (pHx) or sham surgery and sacrificed 24, 42, or 48 hours later. Tissue was analyzed for TGFβ signaling, the mitogenic cytokine response (i.e. tumor necrosis factor alpha, TNFα; interleukin (IL) 6), and liver regeneration.

Partial hepatectomy stimulated a strong regenerative response measured by proliferating cell nuclear antigen positive hepatocytes 42 and 48hr post-pHx in conjunction with elevated expression of IL6, TNFα and Smad2/3 phosphorylation 24hr post-pHx in both hepatocytes and non-parenchymal cells. Surprisingly, Smad3 deficiency led to reduced hepatocyte proliferation 42hr post-pHx which recovered by 48hr, a process which correlated with and was preceded by significant reductions in IL6 expression and signal transducer and activator of transcription 3 phosphorylation, and cyclin D1 induction 24hr post-pHx.

Loss of Smad3 signaling suppresses the expression of key mitogenic cytokines and delays hepatocellular regeneration. Therapies directed at finely regulating Smad3 activation early within the regenerating liver may prove useful in promoting liver cell proliferation and restoration of liver mass.

Keywords

cytokines; liver regeneration; liver signaling; partial hepatectomy; Smad family; Stat3

Introduction

Liver transplantation remains the primary treatment option for patients suffering from chronic liver pathologies including cirrhosis and severe acute liver failure. Limited donor organs have necessitated the use of marginal livers as well as small for size liver grafts including living donor related transplantation. Transplantation of marginal or reduced size liver grafts requires regeneration of tissue (1). Limited or impaired regeneration is a major cause of organ failure following transplantation in these patients (2). Fortunately, the healthy liver possesses the ability to regenerate as much as 70% of its tissue mass within 14 days though a variety of factors have been associated with inhibition of this response (3). Indeed, inflammation associated with ischemic tissue injury, viral infection, and immune-mediated tissue rejection are known to significantly disrupt the regenerative response (4–6). Experimentally, the mechanisms of the regenerative response have been evaluated and it is clear that a number of soluble factors contribute significantly to hepatocyte proliferation and liver regeneration. For example, inhibited hepatocyte growth factor signaling (7), disrupted early hepatocyte proliferation (8) and delayed restoration of organ mass increased the susceptibility of organs to failure. Likewise, loss of normally pro-inflammatory cytokines including IL6 and TNFα significantly suppressed early hepatocyte proliferation and delayed organ re-growth. Downstream activation of signal transducer and activator of transcription (Stat) 3 and nuclear factor kappa B by IL6 and TNFα respectively are critical to the induction of hepatocyte proliferation and survival following tissue loss (9, 10). Together, liver regeneration represents an important and highly regulated mechanism of tissue repair and critical feature for small for size liver grafts.

Counterbalancing the early pro-proliferative genes is the expression and action of transforming growth factor beta (TGFβ) (11). TGFβ mediated activation of Smad proteins, particularly Smad2, 3, and 4 (i.e. the inhibitory Smads), upregulates several inhibitors of cell proliferation including p27^{kip} limiting cellular regeneration in a number of cell lines including hepatocytes (12). Recent studies have highlighted Smad3 as key intracellular signaling molecule activated by the TGFβ receptor upon ligation with active TGFβ (13). TGFβ and associated Smad signaling are known to suppress immune cell function in a number of experimental models including inflammatory bowel disease (14). Within the liver, Smad3 activation promotes hepatic stellate cell activation during severe chemical-induced liver injury and fibrogenesis while also supporting T cell-mediated liver injury through promotion of hepatocellular apoptosis (15, 16). During liver regeneration, TGFβ induction is thought to suppress the proliferation of hepatocytes and limit or terminate the regenerative response (10, 17). The importance of Smad3 in this process has not been investigated though it was hypothesized that Smad3 activation would limit hepatocyte regeneration and promote hepatocellular apoptosis following significant tissue loss. To test this hypothesis, wild type mice or mice deficient in Smad3 were subjected to a partial (70%) hepatectomy and allowed to recover for up to 48 hours. Surprisingly, absence of Smad3 was

associated with decreased early hepatocyte proliferation in conjunction with reduced IL6 production and Stat3 activation. These data highlight, for the first time, the ability of Smad3 signaling to positively regulate the proliferative response through regulation of important pro-proliferative cytokine production.

Materials and Methods

Animals and Treatment

All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals". The conduct of the study was approved by the University Institutional Animal Care and Use Committee. Animals were housed in pathogen free barrier facilities and had free access to water and diet. Male 10–14 week old wild type (wt) C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) and mice deficient in Smad3 (Smad3$^{-/-}$) on a C57Bl/6 background (kindly provided by Dr. Xiao-Fan Wang, Duke University Medical Center (13), were subject to a 70% partial hepatectomy (pHx) or sham surgery for control as published previously (4). After 24h, 42h or 48h, mice were sacrificed and tissue was collected to assess liver damage, cell proliferation, gene expression and transcription factor activity. In addition, to evaluate the cytokine response in wild type or Smad3$^{-/-}$ mice, lipopolysaccharide was injected i.p. at a dose of 2.5mg/kg 6 hours prior to sacrifice. Again, serum and tissue were collected to assess liver injury and the hepatic cytokine response.

Pathologic Evaluation / Terminal UTP Nick End Labeling (TUNEL) Staining

Livers were fixed in 4% buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin to assess histopathology. To assess liver cell death, deparaffinized sections were stained for DNA fragmentation using a commercially available Cell Death Detection Kit (Roche, Mannheim, Germany) according to the manufacturer's recommendations and as previously described (15). Slides were viewed by fluorescent microscopy and images captured with a digital camera (Olympus DP-70, Center Valley, PA).

Immunohistochemistry

Immunohistochemistry was performed with minor modifications as reported previously (18). Deparaffinized liver sections were stained for phosphorylated Smad2 and 3 (pSmad2/3, Santa Cruz, Santa Cruz, CA). In brief, after proteinase K incubation (20μg/ml) for 5 min with consecutive blocking for 20 min using 1% bovine serum albumin diluted in phosphate buffered saline (PBS-1% BSA), sections were incubated with the primary antibody (1:250) for 1h. After washing in PBS, slides were treated with anti-rabbit HRP-conjugated secondary antibody (Amersham, Little Chalfent, UK) at a concentration of 1:250 in PBS-1% BSA. Proliferating cell nuclear antigen (PCNA) and BrdU staining were completed as previously described (4, 19). Immunocomplexes were visualized using diaminobenzidine (Dako, Carpenteria, CA) and signals quantified using Image J (NIH image, www.nih.gov). PCNA quantitation is presented as positive hepatocyte nuclei per 1000 total hepatocytes, indicated as PCNA labeling index.

Total RNA Isolation and Real Time Reverse Transcription-PCR

Total RNA was isolated from whole liver using Trizol reagent (Invitrogen, Carlsbad, CA). Reverse transcription was carried out using Superscript II reverse transcription reagents (Invitrogen) and random hexamers according to the manufacturers direction. Polymerase chain reaction was performed using a 170–9740 MyiQ Single-Color Real-Time PCR Detection System (Biorad, Hercules, CA) according to the manufacturer's instructions. An optimal PCR reaction for all investigated genes was established using the LightCycler–DNA Master SYBR Green I Kit (Roche, Mannheim, Germany). Results were normalized to β-actin using the comparative cT method. The data are presented as mean ± SEM with the sequences of the primers used listed in Table 1.

Western blotting

Cellular proteins were extracted as described previously (20) from whole liver and quantified using a Bio-Rad protein assay (BioRad). Cellular proteins (100μg) were separated by electrophoresis on 8–16% Tris-glycine gels by SDS-PAGE and electrophoretically transferred to a nitrocellulose membrane (Amersham). The membranes were blocked using 5% BSA in TTBS (0.1% Tween-20 in 100 mM Tris-HCl pH 7.5, 0.9% NaCl), followed by incubation with anti-pSmad3, total Smad3, pStat3 and total Stat3, Cyclin D1, and cyclin dependent kinase 4 (CDK4), respectively (all from Cell Signaling Technologies, Burlinghame, UK), at 4°C overnight at a dilution of 1:1000. After washing, membranes were treated with appropriate HRP-conjugated secondary antibody (1:10,000) for 1h at room temperature. Signals were detected using ECL Western Detection Reagent (Amersham). Western blots were quantified using Image J (www.nih.gov) and corrected for their proper control, respectively.

Statistics

Data are presented as the mean ± SEM. The statistical significance of differences between Smad3-deficient mice and wt control groups was determined by comparison of the mean using the independent samples T-test. A *p* value of <0.05 was considered as statistically significant. Statistical analyses were performed using SPSS 11.0 software (SPSS Inc., Chicago, IL).

Results

Smad3 is activated in the Regenerating Murine Liver

To test our hypothesis that Smad3 is activated and therefore might play a role in the regenerating liver, wt mice were subject to a standardized 70% partial hepatectomy or sham surgery. Western blotting showed an increase in pSmad 3 24h post-pHx as shown in Figure 1a and quantification of band density (Figure 1b). Additionally, immunohistochemistry of pSmad 2/3 24h after pHx confirmed the findings of increased phosphorylation of Smad3 which localized to both the nuclei of hepatocytes as well as in non-parenchymal cells in the regenerating liver (Figure 1c). These data highlight the activation of Smad3 within the regenerating liver and implicate it in the function of both hepatocytes and non-parenchymal cell populations.

Smad3 Promotes Early pHx-Induced Liver Regeneration

TGFβ/Smad activation promotes senescence of hepatocytes late in the regenerative process. The function of Smad3 specifically in this process has not been evaluated. It was hypothesized that Smad3 plays a critical intermediary role for connecting TGFβ receptor binding and inhibition of hepatocellular proliferation. pHx promoted significant hepatocellular proliferation as early as 24 hours post-pHx which continued to increase at 42 and 48 hours post-pHx as measured by proliferating cell nuclear antigen positive hepatocyte nuclei (Figure 2a and b). Interestingly, and in contrast to our original hypothesis, Smad3 deficiency reduced hepatocellular proliferation at 42 hours post-pHx as assessed by PCNA[+] hepatocyte nuclei (Figure 2a–b). This was further confirmed by reduced bromodeoxyuridine incorporation, a specific indicator of DNA replication in these cells at 42hr but not 48hr post-pHx (Figure 2c).

To further evaluate the proliferative response, and confirm immunohistochemical findings, total tissue protein was isolated from regenerating liver samples and probed for cyclin D1, CDK4, and PCNA. As shown in Figure 2d, pHx in wild type mice induced cyclin D1 expression at 24hr post-pHx and remained elevated through 48hr post-pHx. Similarly, CDK4, a key activator of the regenerative process in hepatocytes, was also induced at 24hr post-pHx and remained elevated through 48hr post-pHx (21, 22). In the absence of Smad3, induction of CDK4 and cyclin D1 was delayed out to 42 and 48hr respectively. This inhibition of cyclin D1 expression was further confirmed by immunohistochemistry at 24hr post-pHx in Smad3-deficient livers when compared to their wild type pHx treated controls (Figure 2e).

In addition to potentially regulating the regenerative response, TGF/Smad signaling may also promote hepatocellular apoptosis. Indeed, previous studies by our laboratory demonstrated the profound importance of Smad3 in regulating hepatocellular apoptosis following toxin administration (15). To this end, liver sections were evaluated by terminal UTP nick end labeling (TUNEL) staining to evaluate the apoptotic response in this model of murine liver regeneration. pHx did not induce significant hepatocellular apoptosis at any time point examined in either wild type or Smad3-deficient mice (Supplemental Figure 1).

Together, these data highlight the importance of Smad3 signaling in the early regenerative response following major tissue loss in the mouse.

Smad3 Promotes pHx-induced Cytokine Production

To investigate the underlying mechanism by which Smad3 signaling might influence the proliferative response in hepatocytes, cytokine expression was assessed by quantitative PCR for TNFα and IL6, two key pro-inflammatory yet mitogenic cytokines. pHx resulted in significant increases in both TNFα and IL6, but not TGFβ, at 24 and 42hr post-surgery when compared to pre-pHx levels (Figure 3). This is consistent with previous studies by our laboratory demonstrating enhanced mRNA expression of IL6 and TNFα post-pHx (4). Loss of Smad3 led to a significant reduction in IL6 gene expression 24 hours post-pHx and TNFα expression 42hr post-pHx when compared to similarly treated wt mice. While these data are limited to the analysis of gene expression for these factors, they do suggest that Smad3

signaling interacts with pro-mitogenic cytokine production in the regenerating murine liver and highlight a potential mechanism for the impaired regenerative response observed.

Role of Stat3 in the Regenerating Liver

To better define the potential impact of disrupted pro-mitogenic cytokine production on the regenerative response, we focused on the downstream targets of these cytokines, particularly IL6. Stat3 is a key target and regulator of IL6 signaling in regenerating cells including hepatocytes (6). Consistently, loss of Stat3 suppresses the regenerative response of hepatocytes following major tissue loss (23). Given that IL6 expression was reduced, we sought to determine the impact of this reduction on Stat3 activation. As shown in Figure 4, Stat3 is activated early during regeneration in the wt liver as indicated by its level of phosphorylation (24hr post-pHx; Figure 4A) and remains elevated through 48hr post-pHx. Consistent with reduced IL6 production in Smad3 deficient mice, Stat3 phosphorylation is impaired in these mice 24hr post-pHx, a time-point preceding the reductions in liver regenerative response. Stat3 activation recovers, however, at 42 and 48 hours to levels at or above those seen in similarly treated wt mice.

To further define the interactions of Smad3 signaling and Stat3 regulation, two additional regulators of the response were quantified. Suppressor of cytokine signaling 3 (SOCS3) and protein inhibitor of activated stat 3 (PIAS-3) are key regulators of Stat3 activation and downstream targets of Stat3 activation as well (24, 25). Indeed, both SOCS3 and PIAS-3 are induced by Stat3 activation and act as negative feedback regulators to suppress Stat3 function. As shown in Figure 4C, SOCS3 expression is strongly elevated in wt mice 24 hours post-pHx and remains elevated through 48hr post-pHx consistent with the continued activation state of Stat3 in these livers. Figure 4D further confirms the induction of a negative regulator of Stat3 activation, PIAS-3, at 24hr post-pHx in wt mice when compared to pre-pHx levels. Interestingly, and consistent with impaired Stat3 activation, both SOCS3 and PIAS-3 were not induced in Smad3-deficient livers when compared to similarly treated wt mice at 24 or 42hr post-pHx. Together, these data demonstrate reduced Stat3 activation in the Smad3 deficient liver, a process occurring independent of the induction of potential negative regulators of the response, and further suggesting an important connection between Smad3 and IL6 production in the regenerating liver.

Smad3 promotes Endotoxin-induced hepatic IL6 production

It is clear from these studies that Smad3 signaling affects key pro-mitogenic cytokine production, Stat3 activation, and hepatocellular regeneration early during the regenerative response to pHx. Interestingly, immunohistochemistry reveals Smad3 activation, as assessed by its phosphorylation, both in parenchymal and non-parenchymal cells during this early period of regeneration. Kupffer cells (KC), the hepatic macrophage, contribute to inflammatory cytokine production in acute and chronic liver injuries (26). KCs also play a substantive role in liver regeneration, as their loss prolongs the time to restoration of tissue mass (27). The influence of Smad3 activation on hepatic KC responses has not been thoroughly investigated though it is thought that TGFβ-mediated activation of Smad3 likely suppresses their function. As KCs may be a significant contributor to IL6 production in the liver, we sought to address the function of Smad3 in their production of this important pro-

proliferative cytokine (27). As shown in Figure 5, lipopolysaccharide (LPS) administration 6 hours prior to sacrifice does not induce significant TGFβ mRNA synthesis but promotes strong IL6 and TNFα production in conjunction with CD14 expression consistent with numerous previous reports (28). Loss of Smad3 does not affect CD14 induction or alter the TGFβ response but completely blocks IL6 production and limits TNFα mRNA synthesis in response to LPS suggesting that KCs are impaired in their synthesis of key pro-inflammatory but also pro-proliferative mediators in response to a common endogenous activator. These data implicate Smad3 signaling in the regulation of IL6 production by liver, and likely by KCs, and may suggest a potential mechanism by which Smad3 signaling positively regulates early regenerative responses in the hepatectomized animals.

Discussion

The balance between cell proliferation and apoptosis is vital for tissue homeostasis but also regeneration that depends on several growth factors and cytokines (9). Upon binding of TGFβ to its type I and II surface receptor complexes, intracellular Smad2 and 3 are phosphorylated and form a complex with Smad4, which translocates to the nucleus to modulate the transcriptional response by interacting with a variety of factors regulating the expression of target genes (29). Intriguingly, while Smad2 and 4 are required for development, Smad3 function appears dispensable given the survival and health of rodents deficient in its expression (30). Accumulating data would suggest that this factor may be more centrally responsible for regulation of the inflammatory response with redundant developmental support provided by other inhibitor Smads (31–33). This led us to investigate its function in the regenerating liver, where both cellular regeneration and inflammatory responses converge to promote a regulated and balanced restoration of liver mass. Surprisingly, and in contrast to our original hypothesis, global deletion of Smad3 impaired hepatocellular regeneration and interrupted key early IL6 induction and Stat3 activation within the murine liver.

TGFβ and Hepatocyte Regeneration

TGFβ and Smad signaling is associated with cell cycle arrest and is also known to be an inducer of apoptosis (34). TGFβ is significantly increased in regenerating human transplanted livers and likely contributes to cessation of liver growth. Experimentally, overexpression of TGFβ inhibits the proliferative response of hepatocytes following major tissue loss while loss of TGFβ receptor 2 promotes early mitogenic reflexes within hepatocytes. Studies by Zhong and colleagues have confirmed this relationship demonstrating an enhancement in liver regeneration characterized by increased graft size and BrdU incorporation in transplanted rat livers overexpressing Smad7 in conjunction with reduced nuclear Smad2/3 translocation (19). It was therefore hypothesized that loss of Smad3, a key signaling element within the TGFβ cascade, would also promote hepatocyte regeneration following partial hepatectomy similar to that seen in TGFβR2 deficient or Smad7 over-expressing livers. Surprisingly, loss of Smad3 reduced early replicative responses in regenerating hepatocytes within the murine liver. Analysis of both PCNA[+] hepatocytes and BrdU incorporation revealed significantly reduced proliferation at 42 hours post-pHx in conjunction with impaired cyclin D1 and CDK4 expression at 24hr post-pHx.

Intriguingly, hepatocellular proliferation rebounded and overshot the wild type response by 48 hours post-pHx consistent with previous studies characterizing the TGFβ effect and suggesting apparent dueling effects of TGF-Smad3 signaling in the context of liver regeneration, possibly through differential effects on different hepatic cell populations. Indeed, our studies stop short of defining a cell specific effect of TGFb-Smad3 signaling though separate approaches do define a potential disruption in KC in Smad3-deficient mice.

TGFβ signaling and Kupffer cell Function

It is clear that TGFβ plays an important role in non-parenchymal cell function within the liver. Interruption of TGFβ signaling within lymphocytes promotes hepatocellular injury and autoimmune-like hepatitis while this same signaling pathway promotes stellate cell activation and expression of type I collagen (16, 35). TGFβ has also been shown to inhibit pro-inflammatory cytokine production in Kupffer cells in conjunction with their transition toward a more regulatory phenotype (36). Within the current study, loss of Smad3 signaling suppressed IL6 and TNFα production following stimulation with LPS *in vivo* suggesting a potential defect in this response as a mechanism for the delayed regenerative response observed. Studies in our laboratory support a similar role for TGFβ and Smad3 in the induction of TNFα production by hepatic macrophages (Son and Hines, unpublished observation). Administration of TGFβ to hepatic macrophages promoted TNFα production in response to Tlr4 engagement while loss of Smad3 or overexpression of Smad7 suppressed this response. The connection between Smad3 and IL6 production remains unclear. Nath and colleagues recently demonstrated reduced IL6 production in ischemic kidney injury in Smad3-deficient mice (37). IL6 is regulated by a number of factors including nuclear factor kappa B (NFκB), NF-IL6, Fos-Jun, and CAAT/enhancer binding protein (C/EBP) (38). Likewise, soluble mediators including TNFα and IL1 have also been shown to promote its transcription. TGFβ is known to interact with a number of these pathways with its effects being at least partly cell specific. Aoki and others demonstrated the ability of pancreatic stellate cells to produce IL6 in response to TGFβ stimulation *in vitro*, and the coordinate up-regulation of TGFβ in response to IL6 treatment suggesting autocrine loop to promote expression of both (39). Further investigation in bronchial epithelial cells revealed the ability of TGFβ to promote IL6 production, a process which was related to c-Jun N terminal kinase (JNK) activation (40). Activation of NFκB by TGFβ also promotes epithelial to mesenchymal transition (EMT) defining a connection for these signaling pathways (41). Within macrophages, TGFβ signaling in part through the co-receptor endoglin promotes their recruitment and cytokine production, specifically IL1β and IL6, in radiation-induced kidney damage (42). Similarly, in osteoclasts, TGFβ mediated activation of TGF activated kinase 1 (TAK1) promoted Akt activation and subsequent NFκB induction leading to cell survival (43). Thus, it appears that TGFβ-mediated responses may promote inflammatory transcription factor activation and support IL6 production among other cytokines and have potentially pro-proliferative roles in the regenerating murine liver.

TGFβ-Smad3 and the Regenerative Response – Is the IL6-Stat3 axis the connection?

Within the current study, it is clear that Smad3 signaling promotes IL6 production in the regenerating liver, possibly from hepatic KCs, and this induction correlates with hepatic Stat3 activation and cell proliferation. In the liver, IL6 is a major regulator of the acute

phase response, and promotes early liver regeneration (10, 44). Fausto and others demonstrated elevated IL6 early during the regenerative response, a process which was preceded by and associated with TNFα induction (10, 45). Additional experiments using Il6 and TNFα receptor 1 (TNF-R1) knockout mice after pHx demonstrated an impaired S phase progression with defects in hepatocyte proliferation and high mortality rate. In both IL6 and TNFα-R1 knockout mice, the blunted regenerative response could be rescued by treating the animals with IL6 (44). Conversely, overexpression of IL6 has been shown to inhibit the proliferative capacity of hepatocytes within the regenerating liver likely owing to its ability to act as a potent inflammatory mediator and highlighting the importance of a fine tuned pro-proliferative cytokine response during the restoration of lost liver mass (46). The current study has demonstrated an interaction between Smad3 signaling and pro-proliferative cytokine production IL6 and the downstream activation of Stat3. Stat3 signaling is a known regulator of cell survival and proliferation (6). Upon activation by a number of factors including IL6, Stat3 promotes cell survival including induction of anti-apoptotic factors while also promoting cell cycle progression and liver regeneration (23, 47). In support of this notion are studies which show that loss of Stat3 in hepatocytes reduced their proliferation early during regeneration following partial hepatectomy and to a similar degree following carbon tetrachloride induced liver damage (6, 23, 47). Connectivity between Stat3 and Smad3 has also been shown previously. Wierenga and colleagues showed a reduction in IL6-mediated Stat3 activation in the presence of TGFβ in leukemia cells, a process which involved interruption of JAK activation and induction of cellular apoptosis (48). In contrast, induction of protein inhibitor of activated Stat3 (PIAS3), a factor induced by Stat3 activation, significantly increased TGFβ-mediated Smad3 activation suggesting that TGFβ-Smad signaling could be a negative feedback loop to inhibit Stat3 mediated proliferative signals (49). Within the current study, a new connection can be drawn between TGFβ-Smad3 signaling, IL6 production, downstream Stat3 activation, and early hepatocellular regeneration in the hepatectomized liver. It is likely that the net effect of loss of Smad3 early during regeneration is interruption of IL6 production independent of interactions between Smad3 and Stat3 signaling pathways. However, TGFβ mediated Smad3 activation could limit later Stat3 activation in hepatocytes independent of alterations in IL6 induction as Stat3 activation is strongly and significantly increased at 42hr post-pHx in Smad3$^{-/-}$ livers when compared to similarly treated wild type mice. The current study is limited in this regard with respect to understanding the cell specific effects of a loss of Smad3 throughout the regenerative response though it is clear that TGFβ-mediated Smad3 activation provides both pro-proliferative and potentially inhibitor signals during liver regeneration. In sum, however, the current studies do draw a connection between Smad3, IL6 production, and early hepatocellular regeneration following major tissue loss in the mouse but do remain limited in directly defining the cell specific impact of this signaling molecule on IL6 production and liver regeneration.

Conclusion

Understanding the mechanisms of tissue repair and regeneration, particularly following major tissue loss, is critical to defining new treatments to extend or promote organ survival clinically. Early regenerative efficiency, especially within the first 48 hours post-surgery, is critical for graft and recipient survival. Great strides have been made to better define

characteristics favorable for organ survival, both with the organ itself as well as the recipient. The current study highlights Smad3 signaling as a potential, and surprising, positive regulator of IL6 production and hepatocellular proliferation during this critical early period of liver regeneration. These studies are no doubt limited, however, in that the cell specific effects of TGFβ and Smad activation remain unresolved. Recent generation of floxed alleles associated with TGFβ and TGFβ associated signaling will provide the technical framework to assess these processes more specifically. Nevertheless, the current results implicate components of TGFβ signaling in the induction of pro-proliferative responses and provide potential new targets for regulation of hepatocellular regeneration.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Reference List

1. Attia M, Silva MA, Mirza DF. The marginal liver donor--an update. Transpl Int. 2008 Aug; 21(8): 713–724. [PubMed: 18492121]

2. Tucker ON, Heaton N. The 'small for size' liver syndrome. Curr Opin Crit Care. 2005 Apr; 11(2): 150–155. [PubMed: 15758596]

3. Minuk GY. Hepatic regeneration: If it ain't broke, don't fix it. Can J Gastroenterol. 2003 Jul; 17(7): 418–424. [PubMed: 12915914]

4. Hines IN, Kremer M, Isayama F, Perry AW, Milton RJ, Black AL, et al. Impaired liver regeneration and increased oval cell numbers following T cell-mediated hepatitis. Hepatology. 2007 Jul; 46(1): 229–241. [PubMed: 17596893]

5. Umeda Y, Iwagaki H, Ozaki M, Ogino T, Iwamoto T, Yoshida R, et al. Refractory response to growth factors impairs liver regeneration after hepatectomy in patients with viral hepatitis. Hepatogastroenterology. 2009 Jul; 56(93):971–977. [PubMed: 19760923]

6. Moh A, Iwamoto Y, Chai GX, Zhang SS, Kano A, Yang DD, et al. Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery. Lab Invest. 2007 Oct; 87(10):1018–1028. [PubMed: 17660847]

7. Shimizu M, Hara A, Okuno M, Matsuno H, Okada K, Ueshima S, et al. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology. 2001 Mar; 33(3):569–576. [PubMed: 11230736]

8. Seehofer D, Schirmeier A, Bengmark S, Ria Cho SY, Koch M, Lederer A, et al. Curcumin Attenuates Oxidative Stress and Inflammatory Response in the Early Phase after Partial Hepatectomy with Simultaneous Intraabdominal Infection in Rats. J Surg Res. 2008 Dec 31.

9. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997 Apr 4; 276(5309):60–66. [PubMed: 9082986]

10. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology. 2006 Feb; 43 Suppl 1(2):S45–S53. [PubMed: 16447274]

11. Fausto N, Webber EM. Control of liver growth. Crit Rev Eukaryot Gene Expr. 1993; 3(2):117–135. [PubMed: 8324292]

12. Donovan JC, Rothenstein JM, Slingerland JM. Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest. J Biol Chem. 2002 Nov 1; 277(44):41686–41692. [PubMed: 12202478]

13. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol. 1999 Apr; 19(4):2495–2504. [PubMed: 10082515]

14. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001 Aug; 108(4):601–609. [PubMed: 11518734]

15. Kremer M, Perry AW, Milton RJ, Rippe RA, Wheeler MD, Hines IN. Pivotal role of Smad3 in a mouse model of T cell-mediated hepatitis. Hepatology. 2008 Jan; 47(1):113–126. [PubMed: 18023023]

16. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001 Jul; 34(1):89–100. [PubMed: 11431738]

17. Fausto N, Mead JE, Gruppuso PA, Castilla A, Jakowlew SB. Effects of TGF-beta s in the liver: cell proliferation and fibrogenesis. Ciba Found Symp. 1991; 157:165–174. [PubMed: 1649033]

18. Isayama F, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry AW, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol. 2006 Jun; 290(6):G1318–G1328. [PubMed: 16439470]

19. Zhong Z, Tsukada S, Rehman H, Parsons CJ, Theruvath TP, Rippe RA, et al. Inhibition of transforming growth factor-beta/Smad signaling improves regeneration of small-for-size rat liver grafts. Liver Transpl. 2010 Feb; 16(2):181–190. [PubMed: 20104486]

20. Kremer M, Hines IN, Milton RJ, Wheeler MD. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology. 2006 Jul; 44(1): 216–227. [PubMed: 16799967]

21. Jaumot M, Estanyol JM, Serratosa J, Agell N, Bachs O. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes. Hepatology. 1999 Feb; 29(2):385–395. [PubMed: 9918914]

22. Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Grana X, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May; 138(5):1920–1930. [PubMed: 20100483]

23. Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem. 2002 Aug 9; 277(32):28411–28417. [PubMed: 12032149]

24. Starkel P, De SC, Leclercq I, Strain A, Horsmans Y. Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. J Hepatol. 2005 Oct; 43(4):687–695. [PubMed: 16098628]

25. Sun R, Jaruga B, Kulkarni S, Sun H, Gao B. IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: regulation by SOCS3. Biochem Biophys Res Commun. 2005 Dec 30; 338(4): 1943–1949. [PubMed: 16288983]

26. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis. 2007 Nov; 27(4):339–350. [PubMed: 17979071]

27. Meijer C, Wiezer MJ, Diehl AM, Schouten HJ, Schouten HJ, Meijer S, et al. Kupffer cell depletion by CI2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy. Liver. 2000 Feb; 20(1):66–77. [PubMed: 10726963]

28. Garcia-Lazaro JF, Thieringer F, Luth S, Czochra P, Meyer E, Renteria IB, et al. Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock. Immunol Lett. 2005 Nov 15; 101(2):217–222. [PubMed: 16054705]

29. Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol. 1999 Jul; 9(7):274–279. [PubMed: 10370243]

30. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007 Dec; 8(12):970–982. [PubMed: 18000526]

31. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 1999 Mar 1; 18(5):1280–1291. [PubMed: 10064594]

32. Kanamaru Y, Sumiyoshi K, Ushio H, Ogawa H, Okumura K, Nakao A. Smad3 deficiency in mast cells provides efficient host protection against acute septic peritonitis. J Immunol. 2005 Apr 1; 174(7):4193–4197. [PubMed: 15778380]

33. Feinberg MW, Shimizu K, Lebedeva M, Haspel R, Takayama K, Chen Z, et al. Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res. 2004 Mar 19; 94(5): 601–608. [PubMed: 14752027]

34. Fan G, Ma X, Kren BT, Steer CJ. The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene. 1996 May 2; 12(9):1909–1919. [PubMed: 8649852]

35. Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, Wakabayashi K, et al. Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology. 2008 Jun; 47(6):1974–1982. [PubMed: 18452147]

36. Feng M, Wang Q, Zhang F, Lu L. Ex vivo induced regulatory T cells regulate inflammatory response of Kupffer cells by TGF-beta and attenuate liver ischemia reperfusion injury. Int Immunopharmacol. 2012 Jan; 12(1):189–196. [PubMed: 22155100]

37. Nath KA, Croatt AJ, Warner GM, Grande JP. Genetic deficiency of Smad3 protects against murine ischemic acute kidney injury. Am J Physiol Renal Physiol. 2011 Aug; 301(2):F436–F442. [PubMed: 21525133]

38. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000 Jun 16; 275(24):18138–18144. [PubMed: 10747905]

39. Aoki H, Ohnishi H, Hama K, Ishijima T, Satoh Y, Hanatsuka K, et al. Autocrine loop between TGF-beta1 and IL-1beta through Smad3- and ERK-dependent pathways in rat pancreatic stellate cells. Am J Physiol Cell Physiol. 2006 Apr; 290(4):C1100–C1108. [PubMed: 16371439]

40. Ge Q, Moir LM, Black JL, Oliver BG, Burgess JK. TGFbeta1 induces IL-6 and inhibits IL-8 release in human bronchial epithelial cells: the role of Smad2/3. J Cell Physiol. 2010 Nov; 225(3): 846–854. [PubMed: 20607798]

41. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/ Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 2004 Mar 10; 23(5):1155– 1165. [PubMed: 14976548]

42. Scharpfenecker M, Floot B, Russell NS, Stewart FA. The TGF-beta co-receptor endoglin regulates macrophage infiltration and cytokine production in the irradiated mouse kidney. Radiother Oncol. 2012 Sep 27.

43. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res. 2008 Sep 10; 314(15):2725–2738. [PubMed: 18586026]

44. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996 Nov 22; 274(5291):1379–1383. [PubMed: 8910279]

45. Trautwein C, Rakemann T, Niehof M, Rose-John S, Manns MP. Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology. 1996 Jun; 110(6):1854–1862. [PubMed: 8964411]

46. Wustefeld T, Rakemann T, Kubicka S, Manns MP, Trautwein C. Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology. 2000 Sep; 32(3):514–522. [PubMed: 10960443]

47. Xu Y, Feng D, Wang Y, Luo Q, Xu L. STAT3 mediates protection from liver inflammation after partial hepatectomy. Cell Physiol Biochem. 2009; 23(4–6):379–386. [PubMed: 19471105]

48. Wierenga AT, Schuringa JJ, Eggen BJ, Kruijer W, Vellenga E. Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-beta1 is mediated by caspase-dependent and - independent processes. Leukemia. 2002 Apr; 16(4):675–682. [PubMed: 11960349]

49. Long J, Wang G, Matsuura I, He D, Liu F. Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). Proc Natl Acad Sci U S A. 2004 Jan 6; 101(1):99–104. [PubMed: 14691252]

Figure 1.
Smad3 is activated early within the regenerating liver. Wild type mice were subjected to partial (70%) hepatectomy. Phosphorylated Smad3 was then examined by (A) western blot with (B) quantification of band density and (C) immunohistochemistry for pSmad3 at the indicated time-points. Representative data are presented from 4–6 animals per group.

Figure 2.
Smad3 signaling promotes early proliferation within the murine liver. Wild type (WT) or Smad3-deficient mice were subjected to partial (70%) hepatectomy and allowed to recover for 24, 42, or 48 hours. (A) PCNA immunohistochemical analysis of liver sections from various time-points post-pHx. Representative photomicrographs at 200× magnification from indicated time-points. (B) Quantitation of positively stained cells from indicated time-points. Data presented as PCNA labeling index, quantified as positive hepatocyte nuclei per 1000 hepatocytes. (C) Bromodeoxyuridine incorporation 24, 42, or 48 hours post-pHx in WT or Smad3$^{-/-}$ mice. (D) Western blot analysis of cyclin D1 and CDK4 protein expression 0, 24, 42, or 48hr post-pHx with representative immunoblot presented. Coomassie stained gel provided to demonstrate loading equality. (E) Cyclin D1 immunohistochemistry 24 hours following pHx in WT or Smad3-deficient liver sections. Specific staining in (A), (C), and (E) appears as brown to black. *p<0.05 vs. time-matched wild type (WT) mouse with 3–6 mice per group.

Figure 3.
Smad3 signaling promotes IL6 expression within the regenerating liver. Wild type or Smad3-deficient mice were subjected to partial (70%) hepatectomy for up to 48 hours. Gene expression for tumor necrosis factor alpha (TNFα), interleukin 6 (IL6) and transforming growth factor beta (TGFβ) were then quantified at indicated time-points by real time PCR. n=4–6 animals per group. * $p<0.05$ vs. time-matched wild type (WT) control.

Figure 4.
Absence of Smad3 signaling inhibits Stat3 activation within the regenerating liver. Wild type or Smad3-deficient mice were subjected to partial (70%) hepatectomy and Stat3 activation evaluated at 0, 24, 42 or 48 hours post surgery. (A) Representative blot of phosphorylated Stat3 (pStat3) and total Stat3 24 hours following hepatectomy in wild type and Smad3-deficient mice. (B) Quantification of Stat3 activation 0, 24, 42, or 48 hours following hepatectomy. (C) Hepatic PIAS3 and (D) SOCS3 gene expression 0, 24, 42, or 48 hours post-pHx as assessed by quantitative PCR. n=3 animals per group.

Figure 5.
Loss of Smad3 reduces endotoxin-elicited IL6 and TNFα production but not CD14 expression in the murine liver. Wild type or Smad3$^{-/-}$ mice were administered lipopolysaccharide (LPS; 2.5mg/kg) or saline by intraperitoneal injection 6 hours prior to sacrifice. Tissue expression for IL6, TNFα, TGFβ, and CD14 was determined by quantitative PCR. n=4–6 animals per group.

Table 1

Primer list for quantitative PCR measurements

Gene	Forward Primer	Reverse Primer
TNFα	5'-AGCCCACGTAGCAAACCACCAA-3'	5'-ACACCCATTCCCTTCACAGAGCAAT-3'
IL6	5'-GAGGATACCACTCCCAACAGACC-3'	5'-AAGTGCATCATCGTTGTTCATACA-3'
TGFβ	5'-TGACGTCACTGGAGTTGTACGG-3'	5'-GGTTCATGTCATGGATGGTGC-3'
SOCS3	5'-CACAGCAAGTTTCCCGCCGCC-3'	5'-GTGCACCAGCTTGAGTACACA-3'
PIAS3	5'CTGTCACCTGGGGCAACTAT-3'	5'-AGATGAGGGACACTCGCACT-3'
CD14	5'-AGGGTACAGCTGCAAGGCT-3'	5'-CTTCAGCCCAGTGAAAGACA-3'
β actin	5'-AGGTGTGCACCTTTTATTGGTCTCAA-3'	5'-TGTAGTAAGGTTTGGTCTCCCT-3'